
Vivos Therapeutics (VVOS) Stock Forecast & Price Target
Vivos Therapeutics (VVOS) Analyst Ratings
Bulls say
Vivos Therapeutics Inc has witnessed substantial revenue growth, with Q3 FY25 revenues reaching $6.8 million, reflecting a 76% year-over-year increase and a 78% sequential rise, driven significantly by the successful integration of the SCN platform. Service revenues exceeded expectations, more than doubling to $4.6 million, anchored by strong performances in sleep testing and treatment-center revenues, highlighting the efficacy of the Vivos System in addressing sleep-disordered breathing. The company's robust projected growth trajectory is supported by expanding market opportunities, particularly in the Asia Pacific region, alongside reported improvements in treatment outcomes for patients with obstructive sleep apnea.
Bears say
Vivos Therapeutics Inc. has experienced a year-over-year revenue decline of 9% in the first half of 2025, driven by its transition to a new sleep center operations model, indicating potential challenges in establishing its new business framework. Despite a slight quarter-over-quarter revenue increase of 27% in Q2 2025, the overall financial performance has been impacted by reduced gross margins, which fell to 55% due to discounting and a changing product/service mix. The company also faces several significant risks, including heightened competition, regulatory challenges, and ongoing operational losses, all contributing to uncertainties regarding its future profitability and growth potential.
This aggregate rating is based on analysts' research of Vivos Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
Vivos Therapeutics (VVOS) Analyst Forecast & Price Prediction
Start investing in Vivos Therapeutics (VVOS)
Order type
Buy in
Order amount
Est. shares
0 shares